title: SGN-10. Seattle Genetics.
abstract: Seattle Genetics is developing SGN-10 (BR96-SCIT), a single-chain immunotoxin (SCIT) under license from Bristol-Myers Squibb (BMS), as both a monotherapy and in combination with Taxotere (Rhône-Poulenc Rorer) for the potential treatment for cancer [308773]. SGN-10 is currently in phase I clinical trials [308773], [369809], [382807], [408963], [410348]. The compound is a follow-up to SGN-15 (BR96-DOX; BMS) and is potentially more effective and cheaper to manufacture. It delivers a bacterial toxin which is 250-times more potent than BR96-DOX and is one third the size, hence enabling tumor penetration more easily. BMS submitted an IND for SGN-10 in the first quarter of 1996 [200849], [204704]. BMS licensed the SCA-protein (single-chain antigen-binding protein) technology from Enzon in 1993 [352743]. In April 1998, Seattle Genetics completed a licensing agreement with BMS to take over development of SGN-10 [308773].
authors.affiliation: Suzanne_Smith162@hotmail.com
authors.forename: S V
authors.initials: SV
authors.lastname: Smith
mesh_terms: D036002:ADP Ribose Transferases; D000818:Animals; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D001427:Bacterial Toxins; D017321:Clinical Trials, Phase I as Topic; D005098:Exotoxins; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D011993:Recombinant Fusion Proteins / Q000494:pharmacology / Q000627:therapeutic use / Q000633:toxicity; D057127:Single-Chain Antibodies; D013329:Structure-Activity Relationship
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; C115038:BMS-191352 protein, recombinant; D001427:Bacterial Toxins; D005098:Exotoxins; D011993:Recombinant Fusion Proteins; D057127:Single-Chain Antibodies; D036002:ADP Ribose Transferases